U.S., Feb. 6 -- ClinicalTrials.gov registry received information related to the study (NCT06808932) titled 'VK4-116 Phase I Study with Food-Effect' on Jan. 22.
Brief Summary: This first-in-human, randomized, double-blind, placebo-controlled, single ascending dose (SAD), phase I study is designed to assess the safety, tolerability and pharmacokinetics of VK4-116 in healthy volunteers in fasted and fed state.
Study Start Date: Nov. 01, 2025
Study Type: INTERVENTIONAL
Condition:
Opioid Dependence
Opioid Use Disorder (OUD)
Intervention:
DRUG: VK4-116
D3R antagonist
Recruitment Status: NOT_YET_RECRUITING
Sponsor: National Institute on Drug Abuse (NIDA)
Disclaimer: Curated by HT Syndication....